Mini-Reviews in Medicinal Chemistry

Back

Inhibitors of c-jun-N-Terminal Kinase (JNK)

Author(s): Philip LoGrasso and Theodore Kamenecka

Affiliation: Department of Molecular Therapeutics and Drug Discovery, The Scripps Research Institute, 5353 Parkside Drive, Jupiter, FL 33458, USA.

Abstract:

Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.

Keywords: c-jun-N-Terminal Kinase (JNK), mitogen activated protein (MAP), benzothiazole pyrimidines, benzothien-2-yl amides, indazoles, aminopyrimidines, aminopyridines, quinolines

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 8
ISSUE: 8
Page: [755 - 766]
Pages: 12
DOI: 10.2174/138955708784912120
Price: $58